134485-97-5

Usage

Uses

Used in Pharmaceutical Industry:
2,4-BIS-(2-METHYL-IMIDAZOL-1-YL)-PHENYLAMINE is used as a potential anti-cancer drug for its potential to target and treat various types of cancer. Its unique chemical structure allows for specific interactions with biological targets, offering a promising avenue for cancer therapy.
Used in Coordination Chemistry:
2,4-BIS-(2-METHYL-IMIDAZOL-1-YL)-PHENYLAMINE is used as a ligand in coordination chemistry for its ability to form stable complexes with metal ions. This application is crucial in the development of new materials with tailored properties for various applications, including catalysis and sensing.
Used in Organic Synthesis:
2,4-BIS-(2-METHYL-IMIDAZOL-1-YL)-PHENYLAMINE is used as a building block in organic synthesis for its reactivity and potential to form a wide range of organic compounds. Its presence in the synthesis process can lead to the creation of novel molecules with specific functions and properties, useful in various chemical and pharmaceutical applications.
While the specific applications and industries for HMIM are still being explored, its potential in pharmaceuticals, coordination chemistry, and organic synthesis highlight its versatility and importance in scientific research and industrial development. Further studies on its biological and environmental impacts will be essential to fully understand and harness its potential.

InChI:InChI=1/C14H15N5/c1-10-16-5-7-18(10)12-3-4-13(15)14(9-12)19-8-6-17-11(19)2/h3-9H,15H2,1-2H3

Upstream product

• 446-35-5 2,4-Difluoronitrobenzene 
• 134485-96-4 1,1'-(1-nitrobenzene-2,4-diyl)bis(2-methyl-1H-imidazole) 

Relevant academic research and scientific papers

Discovery of 1-(3′-aminobenzisoxazol-5′-yl)-3-trifluoromethyl- N-[2-fluoro-4-[(2′-dimethylaminomethyl)imidazol-1-yl]phenyl] -1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor

Modification of a series of pyrazole factor Xa inhibitors to incorporate an aminobenzisoxazole as the P1 ligand resulted in compounds with improved selectivity for factor Xa relative to trypsin and plasma kallikrein. Further optimization of the P4 moiety led to compounds with enhanced permeability and reduced protein binding. The SAR and pharmacokinetic profile of this series of compounds is described herein. These efforts culminated in 1-(3′-aminobenzisoxazol-5′-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2′-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide (11d), a potent, selective, and orally bioavailable inhibitor of factor Xa. On the basis of its excellent in vitro potency and selectivity profile, high free fraction in human plasma, good oral bioavailability, and in vivo efficacy in antithrombotic models, the HCl salt of this compound was selected for clinical development as razaxaban (DPC 906, BMS-561389).

Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues

A series of novel imidazoquinoxalinones and their aza analogues were prepared by the cyclization of o-amino(1H-imidazol-1-yl)aryls and heteroaryls with carbonyldiimidazole. The compounds were screened for inhibition of Type I and Type IV phosphodiesterase